Core Viewpoint - Lexeo Therapeutics, Inc. is actively engaging with investors through participation in key conferences, highlighting its commitment to advancing genetic medicine for cardiovascular diseases [1][2]. Company Overview - Lexeo Therapeutics is a clinical stage genetic medicine company based in New York City, focused on innovative treatments for cardiovascular diseases [3]. - The company is developing a portfolio of therapeutic candidates targeting genetic causes of conditions such as Friedreich ataxia cardiomyopathy (LX2006) and plakophilin-2 arrhythmogenic cardiomyopathy (LX2020), addressing significant unmet medical needs [3]. Upcoming Events - Management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 12:30 p.m. ET in New York [1]. - The company will also be featured in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 10:40 a.m. ET (virtual) [2]. - Both events will be webcast live, with replays available on the company's website [2].
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February